{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Choi S"],"funding":["National Health Insurance Service, Ilsan Hospital","Korean Gastric Cancer Association"],"pagination":["67-77"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8980600"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Purpose
Tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) are standard adjuvant chemotherapies (ACs) administered after gastrectomy to patients with stage II or III gastric cancer. However, the efficacy of AC in elderly patients remains unclear. The objective of this retrospective multicenter cohort study was to compare the efficacies of S-1 and CAPOX AC in patients aged ≥70 years.Materials and methods
Nine hundred eighty-three patients who were treated with AC using S-1 (768 patients) or CAPOX (215 patients) were enrolled in this study. Each patient underwent AC after curative gastrectomy for stage II or III gastric cancer at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. Relapse-free survival (RFS) and overall"],"journal":["Journal of gastric cancer"],"pubmed_title":["Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study."],"pmcid":["PMC8980600"],"funding_grant_id":["NHIMC2021CR069","KGC0118C1"],"pubmed_authors":["Kim CH","Pak KH","Seo KW","Son YG","Choi S","Jee YS","Oh SJ","Hwang SH","Lee HH","Yoo MW","Hur H","Jeong IH","Lee SI","Jin SH","Kim HI","Min JS","Lee SE","Son MW","Park JM","Chae H","Lee YJ","Park S","Kim S","Choi SI","Kim CY","Lee CM","Lee MS","Kim JH","Jeong SH"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study.","description":"Purpose
Tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) are standard adjuvant chemotherapies (ACs) administered after gastrectomy to patients with stage II or III gastric cancer. However, the efficacy of AC in elderly patients remains unclear. The objective of this retrospective multicenter cohort study was to compare the efficacies of S-1 and CAPOX AC in patients aged ≥70 years.Materials and methods
Nine hundred eighty-three patients who were treated with AC using S-1 (768 patients) or CAPOX (215 patients) were enrolled in this study. Each patient underwent AC after curative gastrectomy for stage II or III gastric cancer at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. Relapse-free survival (RFS) and overall","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-05-29T03:13:16.37Z","creation":"2026-05-29T03:06:19.143Z"},"accession":"S-EPMC8980600","cross_references":{"pubmed":["35425655"],"doi":["10.5230/jgc.2022.22.e6"]}}